Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Alex Renner, Mauricio Burotto, Jose Miguel Valdes, Juan Carlos Roman, Annerleim Walton-Diaz*

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

2 Citas (Scopus)

Resumen

Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

Idioma originalInglés
Páginas (desde-hasta)17562872211029779
PublicaciónTherapeutic Advances in Urology
Volumen13
DOI
EstadoPublicada - 23 jul. 2021

Nota bibliográfica

Publisher Copyright:
© The Author(s), 2021.

Huella

Profundice en los temas de investigación de 'Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?'. En conjunto forman una huella única.

Citar esto